Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CCXI

3 Stocks That Could Make You a Millionaire in the Long Term

With economic growth moderating just enough to keep hopes of a Fed-engineered ‘soft landing’ alive, shares of fundamentally strong, resilient, and growing businesses AT&T (T), Amgen (AMGN), Humana (HUM) could be worth investing in for sustained risk-adjusted returns. Continue reading….

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

Dogs of the Dow: 2 Stocks to Buy and 2 to Hold

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still uncomfortable inflation level and the possible aggressive rate hikes could keep the market volatile. The Dogs of the Dow investment strategy…

StockNews.com

Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout

Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage.

Investors Business Daily

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter. Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike…

Benzinga

ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Dow Jones Industrial Average

Read news from The Economist, FT, and more,
with one subscription

Places

United States

254,425 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.